Juan Luis V.
- Country
- Denmark
- Department
- Department of Urology
Research Overview
- Calcium Electroporation for Non‑muscle‑invasive Bladder Cancer: First‑in‑Human Feasibility, Safety, and Early Efficacy Trial (CALCIFER)
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer
Data & Insights
Has run more than one trial at 7 of 78 partner sites.
Specializations
Bladder Cancer Specialization
This investigator focuses on innovative treatments for various forms of non-muscle invasive bladder cancer, with particular emphasis on managing recurrent cases and those with specific genetic markers.
- FGFR-positive bladder cancer interventions
- Intermediate-risk bladder cancer management
- Recurrent bladder tumor treatments
The investigator's work encompasses intravesical therapeutic approaches and targeted treatments for specific genetic alterations.
Treatment Methodologies
The investigator specializes in comparing different therapeutic approaches for bladder cancer, including chemoablation techniques and traditional surgical interventions.
- Intravesical therapy administration
- Bladder resection procedures
- Adjuvant chemotherapy protocols
Their research explores both conventional and innovative treatment modalities for optimal patient outcomes.
Clinical Outcomes
The investigator's research priorities include evaluating disease-free survival rates and long-term treatment efficacy in bladder cancer patients.
- Treatment response assessment
- Comparative effectiveness studies
- Long-term outcome evaluation
Their work contributes to understanding the effectiveness of various therapeutic interventions in bladder cancer management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.